Age

18–75

Sex

ALL

Healthy volunteers

Not accepted

Fully understood this study and voluntarily signed the informed consent form (ICF);
-≥ 18 years and ≤ 75 years old;
ECOG score 0-1;
Non-squamous NSCLC;
stage IV;
EGFR and ALK negative;
Treatment-naive;
According to RECIST1.1 criteria, there are measurable or evaluable lesions.

Tumor histology or cytology confirmed that it was associated with squamous cell carcinoma or small cell lung cancer;
Patients with severe organ dysfunction were indicated by examination, Exclude subjects with any active, known or suspected autoimmune diseases;
The estimated survival time is less than 3 months.

Serplulimab Combined With Anti-VEGF Antibody in Advanced Lung Adenocarcinoma